Insider Transactions in Q1 2023 at Fate Therapeutics Inc (FATE)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2023
|
John Mendlein |
BUY
Exercise of conversion of derivative security
|
Direct |
28,461
+8.38%
|
$28,461
$1.37 P/Share
|
|
Jan 13
2023
|
John Mendlein |
BUY
Open market or private purchase
|
Direct |
36,631
+11.47%
|
$183,155
$5.43 P/Share
|
|
Jan 12
2023
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
423
+0.25%
|
$423
$1.37 P/Share
|
|
Jan 11
2023
|
John Mendlein |
BUY
Open market or private purchase
|
Direct |
88,048
+26.35%
|
$440,240
$5.67 P/Share
|
|
Jan 10
2023
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
10,917
-6.07%
|
$54,585
$5.24 P/Share
|
|
Jan 10
2023
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
45,907
-10.64%
|
$229,535
$5.24 P/Share
|
|
Jan 10
2023
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,825
-5.18%
|
$39,125
$5.24 P/Share
|
|
Jan 10
2023
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,331
-5.36%
|
$36,655
$5.24 P/Share
|
|
Jan 10
2023
|
Mark Plavsic Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,418
-2.69%
|
$17,090
$5.24 P/Share
|
|
Jan 10
2023
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
11,553
-6.11%
|
$57,765
$5.24 P/Share
|